April 16, 2014

FDA Approves Neurotoxic Flu Drug For Infants Less Than One

pharma influenza FDA Approves Neurotoxic Flu Drug For Infants Less Than One

by Sayer Ji
GreenMedInfo.com

Whereas the flu is self-limiting, the FDA’s capacity for bad decisions is not…

The recent decision by the FDA to approve the use of the antiviral drug Tamiflu for treating influenza in infants as young as two weeks old, belies an underlying trajectory within our regulatory agencies towards sheer insanity.

Tamiflu, known generically as oseltamivir, has already drawn international concern over its link with suicide deaths in children given the drug after its approval in 1999. In fact, in 2004, the Japanese pharmaceutical company Chugai added “abnormal behavior” as a possible side effect inside Tamiflu’s package.  The FDA also acknowledged in its April, 2012 “Pediatric Postmarket Adverse Event Review” of Tamiflu that “abnormal behavior, delirium, including symptoms such as hallucinations, agitation, anxiety, altered level of consciousness, confusion, nightmares, delusions” are possible side effects.[i]

Recent animal research on Tamiflu has found that the infant brain absorbs the drug more readily than the adult brain,[ii]  [iii]lending a possible explanation for why neuropsychiatric side effects have been observed disproportionately in younger patients.

The very mechanism of Tamiflu’s anti-influenza action may hold the key to its well-known neurotoxicity. Known as a neuromindase inhibitor, the drug inhibits the key enzyme within the flu virus that enables it to enter through the membrane of the host cell.  So fundamental is this enzyme that viruses are named after this antigenic characteristic. For instance,  the “N” in H1N1 flu virus is named for type 1 viral neuromindase.

Mammals, however, also have neurimindase enzymes, known as ‘sialidase homologs,’ with four variations identified within the human genome so far; NEU1,NEU2,NEU3 and NUE4.  These enzymes are important for neurological health. For example, the enzyme encoded by NEU3, is indispensable for the modulation of the ganglioside content of the lipid bilayer, which is found predominantly in the nervous system and constitutes 6% of all phospholipids in the brain.

It is therefore likely that neurimindase-targeted drugs like Tamiflu are simply not selective enough to inhibit only the enzymes associated with influenza viral infectivity. They likely also cross-react with those off-target neurimindase enzymes associated with proper neurological function within the host. This “cross reactivity” with self-structures may also explain why the offspring of pregnant women given Tamiflu have significantly elevated risk of birth defects (10.6%) relative to background rates (2-3%), according to a 2009 safety review by the European Medicines Agency.

Beyond the recognition of Tamiflu’s intrinsic toxicity, there are two additional problems with the use Tamiflu in infants:

  1. Infants do not yet have a sufficiently developed blood-brain barrier capable of keeping the chemical out of their rapidly developing brains
  2. Their detoxification systems are not sufficiently developed to remove the chemical rapidly enough to prevent harm

The FDA’s decision to include infants under one as treatable with Tamiflu is all the more disturbing when you consider that a 2010 study published in The Pediatric Infectious Disease Journal found that of 157 evaluable infants (mean age 6.3 months) treated for influenza with Tamiflu, complications due to the medication were found in the majority (54%) of the treated group.

According to the study

Complications were recorded in 84 patients (54%), the most serious of which were meningitis in 1 infant (1%), pneumonia in 9 (6%), and otitis media in 2 (1%).

Are meningitis, pneumonia and otitis media (ear infection) acceptable risks for treating influenza? Apparently for the FDA, it is.

How about death? Is that an acceptable risk of Tamiflu treatment for flu, a self-limiting disease?

In 2011, the International Journal of Vaccine Risk and Safety in Medicine published an article titled, “Oseltamivir and early deterioration leading to death: a proportional mortality study for 2009A/H1N1 influenza,” described 119 reports of Tamiflu-induced death. According to the study:  “of 119 deaths after Tamiflu was prescribed, 38 deteriorated within 12 hours (28 within 6 hours).”

The study concluded:

These data suggest Tamiflu use could induce sudden deterioration leading to death especially within 12 hours of prescription. These findings are consistent with sudden deaths observed in a series of animal toxicity studies, several reported case series and the results of prospective cohort studies. From “the precautionary principle” the potential harm of Tamiflu should be taken into account and further detailed studies should be conducted.

So, how did the FDA justify its decision to consider Tamiflu safe in infants under one year? Did it use controlled, randomized, placebo-controlled trials to ascertain safety?  Of course not. Testing drugs on infants is unethical, and no parent in their right mind would enroll their newborn in such a trial. Lacking definitive evidence of safety, the FDA’s expanded approval in children younger than one year was based on extrapolation of data from previous results in adults and older children.[iv] This, of course, is inappropriate as it denies the aforementioned differences in the susceptibility to drug toxicity and neurotoxicity between infants and older individuals.  It also avoids proper consideration of the studies in the biomedical literature indicating its potential for severe, if not life-threatening toxicity to infants, children and adults alike.

Another concern, not addressed in the FDA announcement, is that as of Dec. 15th, 2010, the World Health Organization has acknowledged that, based on over 300 tested worldwide samples of the 2009 pandemic H1N1 flu, resistance to Tamiflu is growing.[v]  Therefore, treating an infant with Tamiflu-resistant influenza would not only do nothing to combat the infection, but would poison that child and further disable their natural immune response.

The clear winner in the FDA’s decision will be the bottom line of Roche, the manufacturer of this patented chemical.  How much longer can the FDA continue to expect those subject to its regulatory decisions to maintain the illusion that it is interested in the public welfare?

We must remember that infants do not get sick from the flu as a result of Tamiflu deficiency, or flu vaccine deficiency for that matter.  They do get sick from the immune-disrupting effects of synthetic chemicals completely foreign to human physiology (such as Tamiflu), and lack of vital hormone modulating compounds that result from adequate sunlight exposure (vitamin D3), and good nutrition.

For additional information on this topic view our research on natural anti-influenza agents.

Read the full article here: http://www.greenmedinfo.com/blog/fda-approves-neurotoxic-flu-drug-infants-less-one

Flu and Flu Vaccines:
What’s Coming Through That Needle – DVD

flu and flu vaccines whats coming through that needle DVD by dr tenpenny FDA Approves Neurotoxic Flu Drug For Infants Less Than One

More Info
FREE Shipping Available!


0 commentsback to post

Other articlesgo to homepage

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

Merck’s Former Doctor Predicts that Gardasil will Become the Greatest Medical Scandal of All Time

In an interview with Dr. Bernard Dalbergue, a former pharmaceutical industry physician with Gardasil manufacturer Merck, he predicts that Gardasil will become the greatest medical scandal of all time. Dr. Dalbergue believes that at some point in time, the evidence will add up to prove that this vaccine, technical and scientific feat that it may be, has absolutely no effect on cervical cancer and that all the very many adverse effects which destroy lives and even kill young girls, serves no other purpose than to generate profit for the manufacturers.

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

Deadly Medicines and Organized Crime: How big pharma has corrupted healthcare

An important new book by a recognized medical research expert describes Big Pharma as akin to the Mafia. In an interview conducted by our colleagues at ANH-Europe, Dr. Peter C. Gøtzsche exposes the flaws of the drug approval system, our reliance on dangerous drugs, and the deadly co-dependence between regulators and industry. Dr. Gøtzsche is co-founder of the highly respected Cochrane Collaboration and Cochrane Reviews, a leading journal of evidence-based medicine. The interview is particularly timely now that the FDA has decided to remove restrictions on the dangerous drug Avandia.

Dr. Gøtzsche’s new book, Deadly Medicines and Organised Crime: How Big Pharma Has Corrupted Healthcare, points out that the pharmaceutical industry is allowed to test their own drugs, and thus effectively be their own judge. He calls this a threat to safe medicine and asks for open access to all research data, including raw data, because otherwise, data can be easily suppressed and conclusions manipulated by industry.

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical Cannabis is a Threat to the Pharmaceutical Industry

Medical marijuana, or cannabis, is legal in 20 US states, where it is used for a variety of medical conditions such as mood disorders, pain disorders, multiple sclerosis, and even cancer. Parents of children with epilepsy met at a news conference to share their dismay that Governor Mark Dayton refuses to legalize medical marijuana. About 85 percent to 95 percent of Americans are in favor of medical cannabis, and nearly 60 percent are in favor of legalizing marijuana. Cannabis shows outstanding promise as a medicinal plant, largely due to its cannabidiol (CBD) content. Cannabinoids interact with your body by way of naturally occurring cannabinoid receptors embedded in cell membranes throughout your body.

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Leaders of Teaching Hospitals Have Close Ties to Drug Companies, Study Shows

Pharmaceutical company payments to doctors extend far beyond rank-and-file clinicians — and deep into the leadership of America’s teaching hospitals, according to a study published recently in the Journal of the American Medical Association.

A team of researchers at the University of Pittsburgh Medical Center examined the boards of the 50 largest drug companies by global sales (excluding three companies that were not publicly traded). The researchers found that 40 percent — 19 companies — had at least one board member who also held a leadership role at an academic medical center. Sixteen of the 17 companies based in the United States had at least one. Several had more than one. All told, the research team found that 41 of the companies’ 2012 board members held leadership positions at academic medical centers. Six of the 41 were pharmaceutical company executives who served on hospital boards of directors or held other leadership posts.

The authors wrote that when academic medical leaders serve on pharmaceutical company boards, it can lead to conflicts not only for individuals, but for the critically important health care institutions they guide.

Living Sick and Dying Young in Rich America

Living Sick and Dying Young in Rich America

When I read an article in The Atlantic recently with the title: Living Sick and Dying Young in Rich America – Chronic illness is the new first-world problem – it caught my attention. This is the kind of topic we cover on a regular basis here at Health Impact News, but seldom do you read about it in the mainstream media.

There are 3 things that are rather astonishing about the sad state of health in America today:

1. We’re sicker than previous generations, and most of us know it.

2. We don’t seem to care about it too much. It is not headline news.

3. There doesn’t seem to be much motivation to change this fact: it seems to have been accepted as the new “norm.”

Last year, we reported about a study funded by the government and your tax dollars which clearly showed that the United States ranks #1 on healthcare spending, but last in life expectancy among wealthy nations (See:U.S. Ranks First in Healthcare Spending – Last in Life Expectancy). The mainstream media barely even covered this story, and even here at Health Impact News it was probably not even in the top 100 stories read from everything we published last year.

The sad fact seems to be that most Americans have adopted an attitude that the current health situation in the U.S. cannot be changed.

For those few of you who have not drunk the Kool Aid, and still believe you do have control over your health and have choices you can make to live a healthier life, then this article by John Thomas identifying the problems and solutions is for you. Please understand that if enough Americans understand that the healthcare system (which is not really a “healthcare” system at all but a MEDICAL system) is the primary problem and take measures to avoid it, that it would absolutely destroy our economy, since so much of it is dependent on sick people. But maybe our economy is heading for destruction anyway, so don’t let that threat stop you from making healthy choices today.

read more


Get the news right in your inbox!